Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS)
CNY 25.56
(1.43%)
CNY 25.56
(1.43%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 43.78 Million CNY | 1080.77% |
| 2022 | 3.7 Million CNY | -66.66% |
| 2021 | 11.12 Million CNY | 0.0% |
| 2020 | - CNY | -100.0% |
| 2019 | - CNY | 200.0% |
| 2018 | - CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| 2015 | - CNY | 0.0% |
| 2014 | - CNY | 0.0% |
| 2013 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 85.45 Million CNY | 33.3% |
| 2024 Q1 | 40.41 Million CNY | -7.69% |
| 2024 Q2 | 64.1 Million CNY | 58.61% |
| 2023 Q2 | 51.52 Million CNY | -2.27% |
| 2023 FY | 43.78 Million CNY | 1080.77% |
| 2023 Q3 | 48.89 Million CNY | -5.1% |
| 2023 Q4 | 43.78 Million CNY | -10.46% |
| 2023 Q1 | 52.72 Million CNY | 1321.84% |
| 2022 Q3 | 5.97 Million CNY | -17.52% |
| 2022 Q1 | 9.19 Million CNY | -17.35% |
| 2022 FY | 3.7 Million CNY | -66.66% |
| 2022 Q4 | 3.7 Million CNY | -37.9% |
| 2022 Q2 | 7.23 Million CNY | -21.24% |
| 2021 Q2 | 4.46 Million CNY | 0.0% |
| 2021 FY | 11.12 Million CNY | 0.0% |
| 2021 Q4 | 11.12 Million CNY | -9.31% |
| 2021 Q3 | 12.26 Million CNY | 174.37% |
| 2021 Q1 | - CNY | 0.0% |
| 2020 Q3 | - CNY | -100.0% |
| 2020 Q4 | - CNY | 0.0% |
| 2020 FY | - CNY | -100.0% |
| 2020 Q2 | - CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2019 FY | - CNY | 200.0% |
| 2019 Q4 | - CNY | 0.0% |
| 2019 Q3 | - CNY | 0.0% |
| 2019 Q1 | - CNY | 100.0% |
| 2019 Q2 | - CNY | 0.0% |
| 2018 Q4 | - CNY | 0.0% |
| 2018 FY | - CNY | 0.0% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 Q2 | - CNY | 0.0% |
| 2018 Q3 | - CNY | 0.0% |
| 2017 Q4 | - CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |
| 2016 Q4 | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| 2016 Q2 | - CNY | 0.0% |
| 2015 FY | - CNY | 0.0% |
| 2014 FY | - CNY | 0.0% |
| 2013 FY | - CNY | 0.0% |